Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $149.1 million.

  • Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) rose 8.38% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year increase of 8.38%. This contributed to the annual value of $149.1 million for FY2024, which is 7.93% up from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) is $149.1 million, which was up 7.93% from $138.1 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) peaked at $149.1 million during FY2024, and registered a low of $49.0 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $138.1 million (2023), whereas its average is $141.1 million.
  • Data for Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 154.63% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) (Yearly) stood at $49.0 million in 2020, then spiked by 154.63% to $124.7 million in 2021, then grew by 9.04% to $136.0 million in 2022, then climbed by 1.57% to $138.1 million in 2023, then rose by 7.93% to $149.1 million in 2024.